Probiotic Supplement Shows Promise as Adjunct Therapy for Depression in Older Adults, Pilot Trial Finds

A small but rigorously designed clinical trial has strengthened the evidence linking gut health and mood regulation, with practical implications for the millions of older adults managing depression.

Published June 17, 2026, in the Journal of the American Geriatrics Society, the PRODG trial (Efficacy of Adjunct PRObiotics in Moderate Unipolar Depression in Geriatric Patients) enrolled 58 adults aged 60 and older with moderate depression. Participants were randomly assigned to receive a daily probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum (approximately 6 billion CFU) or a matched placebo for 12 weeks, while continuing their prescribed antidepressant regimens.

The probiotic group experienced meaningfully greater reductions in both depressive and anxiety symptoms compared to the placebo group.

Why This Matters

Depression in older adults is prevalent and often treatment-resistant. Standard antidepressants achieve adequate response in roughly half of patients overall, with even lower response rates in geriatric populations. Side effects are more pronounced in this age group, and polypharmacy complicates treatment decisions.

A daily probiotic is inexpensive, available without a prescription, and has a well-established safety profile in healthy older adults. If it can augment the effect of existing antidepressants without significant drug interactions, it represents a low-risk option worthy of clinical discussion.

The caveat is critical: this was a pilot trial of 58 participants. The findings constitute preliminary evidence, not a treatment recommendation.

What the Study Found

The PRODG trial is described by its authors as the first randomized, double-blind, placebo-controlled study specifically testing probiotic adjunct therapy in a geriatric depression population. Both groups showed substantial improvement over 12 weeks — a pattern consistent with the significant placebo response typical of depression trials — but the probiotic group demonstrated meaningfully greater benefit.

Researchers also observed elevated serum levels of brain-derived neurotrophic factor (BDNF), a protein that supports neuron survival and growth, in the probiotic group, along with measurable shifts in gut microbiota composition consistent with enhanced gut-brain axis signaling. The trial did not find significant improvements in quality of life or cognitive performance, possibly due to the small sample size.

Key Limitations

• Sample size: 58 participants limits statistical power and generalizability.
• Population: The trial was conducted in India; applicability to other demographic groups requires further study.
• Confirmation needed: A larger confirmatory trial is planned but has not yet been conducted.

Co-corresponding author Dr. Saibal Das of the Indian Council of Medical Research stated: “The results of our study are novel, and we are now planning a follow-up, larger-scale clinical trial due to the encouraging findings.”

Expert Perspective

The gut-brain axis — the bidirectional communication network between the gastrointestinal microbiome and the central nervous system — has gained substantial scientific credibility over the past decade. Microbial diversity decreases with age, shifting toward pro-inflammatory configurations that may parallel neuroinflammatory processes observed in geriatric depression.

Lead author Dr. Abhinaba Ghosh, physician and neuroscientist at Tata Medical Center, noted: “We found that adding specific strains of probiotics has the potential to enhance improvement in depression and anxiety. We did not see a change in the quality of life of the patients, probably because this is a pilot study and there weren’t enough patients. We plan to address this in a follow-up full-scale clinical trial.”

Psychiatrists reviewing the data have highlighted the sound biological plausibility, established safety profile, and favorable risk-benefit ratio given the low cost, making this a reasonable discussion item between patients and physicians.

Who May Benefit Most

Older adults with depression who have not achieved adequate symptom relief with their current antidepressant regimen are the primary population for whom this discussion is most relevant. Individuals seeking low-risk supplementary options who are otherwise healthy and without contraindications to probiotic use are appropriate candidates.

Immunocompromised individuals — including those undergoing chemotherapy, taking immunosuppressants, or living with HIV — should consult their physician before starting any probiotic, as these supplements carry a small risk of bacterial translocation in severely immunocompromised patients.

Practical Steps for Patients

• If you are an older adult taking antidepressants with inadequate symptom relief, ask your physician whether adding a probiotic supplement is worth considering as an adjunct to current treatment.
• The specific strains used in the trial were Lactobacillus helveticus and Bifidobacterium longum. Products containing these strains are widely available at pharmacies without a prescription.
• Do not stop or change your antidepressant without consulting your physician. The trial demonstrated benefit from adding a probiotic alongside existing treatment, not replacing it.
• If you are immunocompromised or have serious gastrointestinal conditions, consult your physician before starting any probiotic supplement.
• Monitor for the larger confirmatory trial, which the research team indicates is in planning.

Cost and Access

Probiotic supplements are widely available at pharmacies and grocery stores without a prescription, typically costing $15 to $40 per month. They are not covered by most insurance plans but are generally accessible without financial hardship. While a physician’s recommendation is not required for purchase, discussing any supplement change with your prescribing physician is advisable to rule out contraindications with existing medications.

Next Steps

The research team has announced plans for a larger, full-scale confirmatory trial, though no public timeline has been specified. Until those results are available, the PRODG findings should be treated as promising preliminary evidence warranting further study — not as established treatment guidance.

The Bottom Line

A well-designed pilot trial found that older adults with depression who added a daily probiotic to their antidepressant regimen showed greater symptom improvement than those on placebo, supported by corresponding biological markers. The evidence remains preliminary, the sample is small, and a larger trial is needed. However, the favorable safety profile, low cost, and plausible mechanism make a risk-benefit conversation with a physician reasonable. For older adults not achieving adequate relief from antidepressants alone, this is worth discussing with your doctor.

Source link